Phase Iii Study of Craniospinal Radiation Therapy Followed by Adjuvant Chemotherapy for Newly Diagnosed Average-risk Medulloblastoma.
From: Division of Neurology, Children’s National Medical Center, Washington, DC 20010, USA. rpacker@cnmc.org
Journal of clinical oncology : official journal of the American Society of Clinical Oncology
- Publish Date: Sep 2006
- ISSN: 1527-7755
- Volume: 24
- Issue: 25
- Pages: 4202-8
- Medium: Internet
- Language: English
- Citation (JAMA): Packer Roger J, Gajjar Amar, Vezina Gilbert, et al. Phase Iii Study of Craniospinal Radiation Therapy Followed by Adjuvant Chemotherapy for Newly Diagnosed Average-risk Medulloblastoma.. J. Clin. Oncol. Sep 2006;24:4202-8
Abstract
PURPOSE: To determine the event-free survival (EFS) and overall survival of children with average-risk medulloblastoma and treated with reduced-dose craniospinal radiotherapy (CSRT) and one of two postradiotherapy chemotherapies. METHODS: Four hundred twenty-one patients between 3 years and 21 years of age with nondisseminated medulloblastoma (MB) were prospectively randomly assigned to treatment with 23.4 Gy of CSRT, 55.8 Gy of posterior fossa RT, plus one of two adjuvant chemotherapy regimens: lomustine (CCNU), cisplatin, and vincristine; or cyclophosphamide, cisplatin, and vincristine. Results Forty-two of 421 patients enrolled were excluded from analysis. Sixty-six of the remaining 379 patients had incompletely assessable postoperative studies. Five-year EFS and survival for the cohort of 379 patients was 81% +/- 2.1% and 86% +/- 9%, respectively (median follow-up over 5 years). EFS was unaffected by sex, race, age, treatment regimen, brainstem involvement, or excessive anaplasia. EFS was detrimentally affected by neuroradiographic unassessability. Patients with areas of frank dissemination had a 5-year EFS of 36% +/- 15%. Sixty-seven percent of progressions had some component of dissemination. There were seven second malignancies. Infections occurred more frequently on the cyclophosphamide arm and electrolyte abnormalities were more common on the CCNU regimen. CONCLUSION: This study discloses an encouraging EFS rate for children with nondisseminated MB treated with reduced-dose craniospinal radiation and chemotherapy. Additional, careful, step-wise reductions in CSRT in adequately staged patients may be possible.
Mesh Headings (Keywords): Adolescent, Adult, Antineoplastic Combined Chemotherapy Protocols, Cerebellar Neoplasms, Chemotherapy, Adjuvant, Child, Child, Preschool, Cisplatin, Cyclophosphamide, Disease-Free Survival, Female, Humans, Lomustine, Male, Medulloblastoma, Neoplasm Staging, Neoplasms, Second Primary, Prognosis, Radiotherapy Dosage, Radiotherapy, Adjuvant, Risk Factors, Survival Analysis, Vincristine
Check for Full Text / PubMed Unique Identifier (PMID): 16943538
This abstract is part of PubMed, a service of the U.S. National Library of Medicine. PubMed includes more than 17 million citations from MEDLINE and other life science journals for biomedical articles. See Copyright and Disclaimers.
Linked medical terms appearing on this page are added by Healia to help readers find more information and are not part of the original PubMed document.
The data herein was last updated on July 8th, 2008 and may not reflect the most current and accurate data available from NLM.